

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI RALPH A. LOREN GIULIO A. DeCONTI, JR. ANN LAMPORT HAMMITTE ELIZABETH A. HANLEY AMY BAKER MANDRAGOURAS ANTHONY A. LAURENTANO KEVIN J. CANNING JANE E. REMILLARD DeANN FORAN SMITH PETER C. LAURO JEANNE M. DIGIORGIO DEBRA J. MILASINCIC, Ph.D. DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER

CYNTHIA L. KAI MEGAN E. WILLIAMS, Ph.D. RICHÁ NAND MICHAEL PHILLIPPS * LISA M. DIROCCO HATHAWAY P. RUSSELL ***

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.**
CYNTHIA M. SOROOS
PETER W. ISMI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFIELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. MCPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
PETER A. DIMATTIA
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only

** Passed the Patent Bar Examination

*** Admitted in TX only

VINCENT P. LOCCISANO

MERIDETH C. ARNOLD

ECH CE

November 13, 2001

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Patent Application Serial No.: 09/852,400 Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Psoriasis

Inventors: William L. Trepicchio et al.

Filed: May 9, 2001

Our Ref. No.: GFN-5405CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Information Disclosure Statement;
- 2. PTO Form 1449;
- 3. Copies of references cited in PTO Form 1449; and
- A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

November 13, 2001

Date Date

Amy E. Mandragouras, Esq. Reg. No. 36,207

Respectfully submitted,

LAHIVE & CQCKFIELD, LLP

Amy E Mandragouras, Esq.

Reg. No. 36,207

Attorney for Applicants



1AN 0 2 2002

In rathe application of: William L. Trepicchio et al.

Serial No.: 09/852,400

Filed: May 9, 2001

For: Compositions, Kits, and Methods for

Identification, Assessment, Prevention, and Therapy

of Psoriasis

Attorney Docket No.: GFN-5405CP

Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1623

Examiner:

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington,

D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Amy E. Mandragouras, Esq.

Reg. No. 36,207

Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras, Esq.

Reg. No. 36,207

Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: November 13, 2001

AEM/CLK/SXH/ipc

Enclosures

U.S. PATENT DOCUMENTS POPULICATION SCITED BY APPLICANT May 9, 2001 MINIMAL MAY 1, 2001 MINIMAL MINI	<u> </u>	is Time							et <u>1 o</u> f 2		
LIST OF PUBLICATIONS CITED BY APPLICANT William L. Trepicchio et al. William L. Trepicchio et	1		ILE OF FORM PTO-1449	COMMERCE		1	3	SERIAL NO. 09/852,400	· 空		
FOREIGN PATENT DOCUMENTS CASS CA										5	
U.S. PATENT DOCUMENTS DOCUMENT MANNEER DATE NAME DATE DOCUMENTS DOCUMENTS DOCUMENT MANNEER DATE	1	1	Use several sneets it	necessary)	William L. Irepic	chio et ai	GROUP			
FOREIGN PATENT DOCUMENTS CLASS SUBCLASS TRANSPORMENT) <u>(a)</u>			May 9, 2001		1623		~_3	
As Capon F, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;55(6):137-40 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Golub TR, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1995 Mar;98(3):302-9 Examiner			, S. J.	U.S. P/	ATENT DOC	UMENTS			- 6.0		
As Capon F, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;55(6):137-40 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Golub TR, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1995 Mar;98(3):302-9 Examiner	EXAMINEI INITIAL	- R	DOCUMBO NUMBER	DATE		NAME	CLASS	SUBCLASS	CO COLING OF APPRO	DATE	
OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E lalpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner		1	PHADEN						Name of the last	FRIME	
OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E lalpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner		J.		FOREIGN	PATENT DO	CUMENTS	<u></u>	<u> </u>			
OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SI,, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner			DOCUMENT NUMBER		17112.5.		CLASS	SUBCLASS	TRANSI	LATION	
A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 A2 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 A3 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9									Į.		
A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 A2 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 A3 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9											
A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 A2 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 A3 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9								1	<u> </u>		
A1 Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 A2 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 A3 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9			OTHERS (in	cludina Aut	thor Title. Da	ete Pertinent Pages	Ftc.)				
chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8 Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner		A1						pion for pso	oriasis a	at	
Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Ad Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner	l	1	1 1			-		3	/****		
dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7 Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner		A2						e pyruvate			
chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800 Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 Bisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Bisen MB, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Bisen MB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Bisen MB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Carbonator Tymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Date Considered			dehydrogenase E	E1alpha sub	bunit gene. I	Hum Mol Genet. 1	1997 Aug	;;6(8):1361-	-7	-	
Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner		A3							-		
resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered											
Arch Dermatol. 1997 Dec;133(12):1514-22 A5 Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 A6 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 A7 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		A4									
Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered	1	1									
human cancer. Nat Med. 1997 Oct;3(10):1137-40 Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		45					+h	· · · · · · · · ·		1 :	
Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		Α5					erve as ui	e angrogen	ic swite	ch in	
Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner							torne P	200			
Fredriksson T, et al. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44 A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered							Wide cap	ression par	icino. 1	roc	
A8 Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 A9 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 A10 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		A7					new reti	noid. Dern	natologi	ica.	
Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered	,	• }			, boor	Sint married	1110	IIVIG	,		
by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		A8			classification	on of cancer: class	discover	y and class	predict	tion	
suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered			by gene expression	on monito	ring. Scienc	e. 1999 Oct 15;28	6(54 <u>39):5</u>	531-7	·		
May;1(5):442-7 Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		A9							L-2)		
Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered	.			ry immune	e, but not ke	ratinocyte, pathog	enic basis	s. Nat Med	. 1995		
effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		-10		- 1.			· · · · · · · · · · · · · · · · · · ·				
Dermatol. 1992 Mar;98(3):302-9 Examiner Date Considered		ATU				•	-			èd	
Examiner Date Considered					•	l epidermai regene	rative ma	ituration. J	Invesi		
	Examir	er l	Dermatol, 1774 IV	/lar;90(3)		Date Considered		·····			
					. [*	Date Consuciou	_	_			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant	*EXAM	INER:									

-					Sheet 2 c	of 2—1					
		MILE C	F FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE.	ATTY DOCKET NO	SERIAL NO.	9					
REV 7-80			PATENT AND TRADEMARK OFFICE	GFN-5405CP	69/852,400	<u> </u>					
لإ	STO	E.P	UBLICATIONS CITED BY APPLICANT	APPLICANT	,						
1/2/	PE	: (Ų	several sheets if necessary)	William L. Trepicchio et	GROUP						
γS		_	21		1623	田 3					
	1 2	SOUS		May 9, 2001	102.0	_					
JAN	,		OTHERS (including Author Title De	to Portinant Dagge Eta \		00 <u>/</u>					
OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Pathogenesis of psoriasis, J. Invest Dermatol, 1990, Jun; 94(6, Suppl):135S-140S											
	& TRA	EM	Rrueger JG, et al. Role of growth factor	rs, cytokines, and their red	eptors in the	8					
			pathogenesis of psofiasis: 3 threst Dell	nator. 1990 Jun, 9 1(0 Bup)	1).1338-1408						
	B2		Tamayo P, et al. Interpreting patterns of gene expression with self-organizing maps:								
		l	methods and application to hematopoie	etic differentiation. Proc N	atl Acad Sci U	SA.					
			1999 Mar 16;96(6):2907-12								
	В3		Trepicchio WL, et al. Interleukin-11 therapy selectively downregulates type I cytokine								
			proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999 Dec;104(11):1527-37								
	B4					1327-37					
	64		Trepicchio WL, et al. IL-11 regulates m								
			inhibition of nuclear factor-kappaB. J I	mmunol. 1997 Dec 1;1390	(11):5661-70						
		-									
					1						
		\dashv									
			a anno ano agree de la companya del companya de la companya del companya de la c								
				· · · · · · · · · · · · · · · · · · ·							
		-									
		ᅱ									
		_									
		ı									
		一									
		_									
Exami	ner			Date Considered	·						
-Adiiii			1	Date Considered							
*EXAN	IINER:	_	Initial if reference considered, whether or not	citation is in conformance with MP	EP 609; Draw line thro	ough					
	citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										